How HIV affects the gut barrier function
Molecular mechanisms underlying HIV related intestinal epithelial barrier dysfunction
This study is looking at how HIV affects the gut's ability to keep harmful germs out, which can cause ongoing health problems, even for people on treatment, and it hopes to find new ways to help prevent these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11007382 on NIH RePORTER |
What this research studies
This research investigates the ways in which HIV infection disrupts the function of the intestinal barrier, which can lead to serious health issues for individuals living with HIV. The study focuses on understanding how microbial translocation across a damaged epithelial barrier contributes to chronic inflammation and immune activation, even in patients receiving effective antiretroviral therapy. By exploring the molecular mechanisms involved, the research aims to identify potential therapeutic targets to prevent inflammation-related complications associated with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV, particularly those experiencing gastrointestinal issues or chronic inflammation.
Not a fit: Patients who are not living with HIV or those who do not have gastrointestinal complications related to their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve gut health and reduce inflammation-related complications in people living with HIV.
How similar studies have performed: Previous research has shown promising results in understanding the relationship between HIV and intestinal health, suggesting that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Parkos, Charles a — University of Michigan at Ann Arbor
- Study coordinator: Parkos, Charles a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.